MEG3

Gene basic information

symbol MEG3
name maternally expressed 3 (non-protein coding)
location 14q32.2
alias_symbol GTL2|NCRNA00023|LINC00023|onco-lncRNA-83
alias_name non-protein coding RNA 23|long intergenic non-protein coding RNA 23
Tissuebladder,bone,bone marrow,breast,cervix,colorectum,endometrium,gallbladder,kidney,liver,lung,nervous system,others,ovary,pancreas,prostate,stomach,thyroid,
Canceracute myelocytic leukemia,bladder cancer,breast cancer,cervical cancer,colorectal cancer,endometrial cancer,gallbladder cancer,gastric cancer,glioma,hepatic cancer,lung adenocarcinoma,lung cancer,myelodysplastic syndrome,non-small-cell lung cancer,osteosarcoma,ovarian cancer,pancreatic cancer,prostate cancer,renal cancer,thyroid cancer,tongue squamous cell cancer,


Description

MEG3 is a well-studied tumor suppressor gene. It is lower in thyroid carcinoma (1), lung cancer (2), gastric cancer (3), hepatic carcinoma (4), osteosarcoma (5), pancreatic cancer (6), colorectal cancer (7), renal cell carcinoma (8), prostate cancer (9), cervical carcinoma (10) and endometrial carcinoma (11). MEG3 expression level is associated with clinicopathological parameters such as tumor size, TNM stage, lymph node metastasis, prognosis (12, 7, 13, 5). Cell functional studies reveal that MEG3 regulates cancer cell proliferation, migration, metastasis, invasion and apoptosis (10, 13, 1). At molecular level, MEG3 can bind to miR-181 (13) and Rac1 (1). Moreover, MEG3 can regulate cell cycle related proteins (10, 9) and apoptosis regulators (8, 8, 9, 10), thereby participating in cancer progression. Besides, MEG3 also influences chemotherapy resistance (14).


Cancer related information

download as excel csv txt

LncRNA tissue cancer type expression level oncogene/suppress gene pathway binding gene/factor associated gene/factor proliferation apoptosis migration EMT invasion metastasis prognosis tag PMID
0 MEG3 bone marrow acute myelocytic leukemia / / - epigenetic modification 19595458
1 MEG3 bone marrow myelodysplastic syndrome / / - epigenetic modification 19595458
2 MEG3 liver hepatic cancer down TS +mir-29a epigenetic modification 21625215
3 MEG3 nervous system glioma down TS P53+ - + 22234798
4 MEG3 bladder bladder cancer down TS LC3-II- - + 23295831
5 MEG3 cervix cervical cancer down TS p53+,caspase-3+, cyclin B1-,CDK1- - + 23790166
6 MEG3 stomach gastric cancer down TS p53+ - + + epigenetic modification 24006224
7 MEG3 lung non-small-cell lung cancer down TS p53+,MDM2- - + + 24098911
8 MEG3 others tongue squamous cell cancer down TS +miR-26a - + + 24343426
9 MEG3 stomach gastric cancer down / DNMT-1-,MiR-148a+ - epigenetic modification 24515776
10 MEG3 ovary ovarian cancer down TS p53+ epigenetic modification 24859196
11 MEG3 colorectum colorectal cancer down TS - + 25636452
12 MEG3 liver hepatic cancer down TS p53+,+UHRF1 - + + epigenetic modification 25641194
13 MEG3 liver hepatic cancer down TS +UHRF1 - + + 25641194
14 MEG3 lung lung adenocarcinoma down TS p53+,Bcl-xl- + chemotherapy resistance 25992654
15 MEG3 thyroid thyroid cancer down TS Rac1- - - 25997963
16 MEG3 lung lung cancer / / WNT/β‑catenin p53,β‑catenin,survivin chemotherapy resistance 26059239
17 MEG3 kidney renal cancer down TS Bcl-2-,procaspase-9+,cytochrome c+ - + 26223924
18 MEG3 stomach gastric cancer down TS miR-141+ - + 26233544
19 MEG3 stomach gastric cancer down TS miR-181 Bcl-2- - + - - - 26253106
20 MEG3 liver hepatic cancer down TS p53+ 26444285
21 MEG3 cervix cervical cancer down TS miR-21-5p-,p53+,caspase-3+ - + 26574780
22 MEG3 prostate prostate cancer down TS Bcl-2-,Bax+,caspase-3+,Cyclin D1- - + - 26610246
23 MEG3 nervous system glioma down TS p53 pathways DNMT1- epigenetic modification 26676363
24 MEG3 gallbladder gallbladder cancer down TS p53+,cyclin D1-,ki-67-,caspase-3+ - + 26812694
25 MEG3 bone osteosarcoma down / + 26823857
26 MEG3 pancreas pancreatic cancer down TS p53+ - chemotherapy resistance 26850851
27 MEG3 colorectum colorectal cancer / / SNP 26934323
28 MEG3 breast breast cancer down TS P53+,P21+,MDM2- - - - 27166155
29 MEG3 breast breast cancer down + 28051255
30 MEG3 endometrium endometrial cancer down TS Notch signaling Notch1-,Hes1- - 27470401

Expression profile

adipose adrenal brain breast colon heart kidney leukocyte liver lung lymph node ovary prostate skeletal muscle testis thyroid tissue 0 5 10 15 20 25 30 35 fpkm 0.8 0.4 12.0 2.0 0.9 0.8 0.7 0.0 0.7 2.0 1.0 37.0 2.0 0.2 4.0 0.6 MEG3

Expression profile in human body map

TCGA-BLCA TCGA-BRCA TCGA-CESC TCGA-HNSC TCGA-KICH TCGA-KIRC TCGA-KIRP TCGA-LIHC TCGA-LUAD TCGA-LUSC TCGA-PRAD TCGA-STAD TCGA-THCA TCGA-UCEC tissue 0.0 0.5 1.0 1.5 2.0 2.5 3.0 fpkm MEG3 type normal tumor

Expression profile in TCGA


Genomic feature visualization


Sequence

External link



Literature

[1]. Wang C, Yan G, Zhang Y, Jia X, Bu P (2015). Long non-coding RNA MEG3 suppresses migration and invasion of thyroid carcinoma by targeting of Rac1. Neoplasma 62(4): 541-9. link pubmed
[2]. Lu KH, Li W, Liu XH, Sun M, Zhang ML, et al. (2013). Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer 13: 461. link pubmed
[3]. Zhou X, Ji G, Ke X, Gu H, Jin W, et al. (2015). MiR-141 Inhibits Gastric Cancer Proliferation by Interacting with Long Noncoding RNA MEG3 and Down-Regulating E2F3 Expression. Dig Dis Sci 60(11): 3271-82. link pubmed
[4]. Zhu J, Liu S, Ye F, Shen Y, Tie Y, et al. (2015). Long Noncoding RNA MEG3 Interacts with p53 Protein and Regulates Partial p53 Target Genes in Hepatoma Cells. PLoS One 10(10): e0139790. link pubmed
[5]. Tian ZZ, Guo XJ, Zhao YM, Fang Y (2015). Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma. Int J Clin Exp Pathol 8(11): 15138-42. link pubmed
[6]. Hu D, Su C, Jiang M, Shen Y, Shi A, et al. (2016). Fenofibrate inhibited pancreatic cancer cells proliferation via activation of p53 mediated by upregulation of LncRNA MEG3. Biochem Biophys Res Commun 471(2): 290-5. link pubmed
[7]. Yin DD, Liu ZJ, Zhang E, Kong R, Zhang ZH, et al. (2015). Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Tumour Biol 36(6): 4851-9. link pubmed
[8]. Wang M, Huang T, Luo G, Huang C, Xiao XY, et al. (2015). Long non-coding RNA MEG3 induces renal cell carcinoma cells apoptosis by activating the mitochondrial pathway. J Huazhong Univ Sci Technolog Med Sci 35(4): 541-5. link pubmed
[9]. Luo G, Wang M, Wu X, Tao D, Xiao X, et al. (2015). Long Non-Coding RNA MEG3 Inhibits Cell Proliferation and Induces Apoptosis in Prostate Cancer. Cell Physiol Biochem 37(6): 2209-20. link pubmed
[10]. Qin R, Chen Z, Ding Y, Hao J, Hu J, et al. (2013). Long non-coding RNA MEG3 inhibits the proliferation of cervical carcinoma cells through the induction of cell cycle arrest and apoptosis. Neoplasma 60(5): 486-92. link pubmed
[11]. Guo Q, Qian Z, Yan D, Li L, Huang L (2016). LncRNA-MEG3 inhibits cell proliferation of endometrial carcinoma by repressing Notch signaling. Biomed Pharmacother 82: 589-94. link pubmed
[12]. Zhang J, Yao T, Wang Y, Yu J, Liu Y, et al. (2016). Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21. Cancer Biol Ther 17(1): 104-13. link pubmed
[13]. Peng W, Si S, Zhang Q, Li C, Zhao F, et al. (2015). Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression. J Exp Clin Cancer Res 34: 79. link pubmed
[14]. Liu J, Wan L, Lu K, Sun M, Pan X, et al. (2015). The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma. PLoS One 10(5): e0114586. link pubmed



© Bioinformatics Group of XTBG